RxDoctor Payments Data

Thomas Goodwin, DO

Family Medicine · Kalamazoo, MINPI 1568481448

Payments from drug & device makers

$576in general payments, 2019–2025

Across 18 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$186
  • Boehringer Ingelheim$124
  • AstraZeneca$104
  • GSK$69
  • AbbVie$41
  • Abbott$20
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$576 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$40,818
Medicare patients
196
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide27$41,498
OzempicSemaglutide28$38,877
EliquisApixaban21$27,008
FarxigaDapagliflozin Propanediol46$26,384
JardianceEmpagliflozin27$21,351
Breo ElliptaFluticasone/Vilanterol25$11,321
JanuviaSitagliptin Phosphate14$10,423
MyrbetriqMirabegron12$9,729
TradjentaLinagliptin12$6,058
Lidocaine16$5,161
Dicyclomine Hcl27$4,217
Fentanyl59$4,101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen200$3,986
Gabapentin96$3,360
Atorvastatin Calcium177$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$186$38,87728 claims
Boehringer IngelheimJardiance, Tradjenta$124$27,40939 claims
AstraZenecaFarxiga$104$26,38446 claims
GSKBreo Ellipta$69$11,32125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →